NVP ADW 742

Key Product Details

Product Description

NVP ADW 742 is an ATP-competitive inhibitor of IGF1R (IC₅₀ in the range of 0.1-0.2 μM). Also inhibits c-Kit kinase activity (IC₅₀ in the range of 3-5 μM). Exhibits a synergistic effect with Imatinib (Cat. No. 5906), enhancing the sensitivity of multiple small cell lung cancer cell lines to the chemotherapeutics Etoposide (Cat. No. 1226) and Carboplatin (Cat. No. 2626).

Product Specifications for NVP ADW 742

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for NVP ADW 742

The following data is based on the product molecular weight 453.58.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.41 mL	22.05 mL	44.09 mL
2.5 mM	0.88 mL	4.41 mL	8.82 mL
5 mM	0.44 mL	2.20 mL	4.41 mL
25 mM	0.09 mL	0.44 mL	0.88 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Warshamana-Greene The Ins-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol.Cancer Ther. 2004 PMID: 15141010
• Zhou The Ins-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy. Oncol. Rep. 2011 PMID: 21455580
• Warshamana-Greene The Ins-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin.Cancer Res. 2005 PMID: 15746061

Product Documents for NVP ADW 742